AbbVie Inc . (NYSE:ABBV), currently trading at $190.14, has demonstrated resilience and strategic foresight as it navigates the loss of exclusivity for its blockbuster drug Humira. The ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $183.9 which represents a slight increase of $8.25 or 4.70% from the prior close of $175.65. The stock opened at $187.3 and touched a low ...

AbbVie Inc.’s stock rose 5% early Friday to lead S&P 500 gainers premarket, after the drug company beat fourth-quarter ...

AbbVie Inc. (NYSE:ABBV) shares are trading higher on Friday. The company reported fourth-quarter adjusted earnings per share ...

AbbVie reported strong Q4 results, driven by Skyrizi, Rinvoq, neuroscience products, and eye care. Click here to find out why ...

AbbVie Inc. (NYSE:ABBV) discovers, develops, manufactures and sells pharmaceuticals worldwide. It is set to report the Q4 ...

AbbVie Inc. closed 15.68% short of its 52-week high of $207.32, which the company achieved on October 31st.

Jeffrey Stewart; Executive Vice President, Chief Commercial Officer; AbbVie Inc Carrie Strom; Senior Vice President, AbbVie and President, Global Allergan Aesthetics; AbbVie Inc Roopal Thakkar ...

The North Chicago-based drugmaker is relying on newer treatments to make up for falling sales of Humira, its aging ...

Learn more about whether AbbVie Inc. or Genmab A/S is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best cancer stocks to buy. Cancer is the second leading cause of death across the globe ...